A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma. (18th May 2015)

• Record Type: Journal Article
• Authors: Sullivan, Ryan J.; Ibrahim, Nageatte; Lawrence, Donald P.; Aldridge, Julie; Giobbie-Hurder, Anita; Hodi, F. Stephen; Flaherty, Keith T.; Conley, Christine; Mier, James W.; Atkins, Michael B.; McDermott, David F.
• Is Part Of: Oncologist. Volume 20:Number 6(2015)
• Page Start: 617
• Page End: 618
• Publication Date: 2015-05-18
• Subjects: Oncology -- Periodicals; Tumors -- Periodicals; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Oncology; Tumors; Neoplasms; Electronic journals; Periodicals; Periodicals; 616.994
• DOI: 10.1634/theoncologist.2015-0105
• Languages: English
• ISSNs: 1083-7159

Abstract

Abstract: Lessons Learned : This study is a rare example of effective doses of both targeted agents being both administered and tolerated. This combination should not be used in melanoma. Background: Sorafenib and bortezomib affect BCL family member expression. We previously demonstrated that bortezomib augmented sorafenib-mediated cytotoxicity in melanoma cell lines in vitro. We aimed to combine sorafenib 400 mg b.i.d. with increasing doses of weekly bortezomib. Methods: Patients with metastatic melanoma were enrolled in dose-escalation cohorts to determine the maximum tolerated dose (MTD) of sorafenib (twice daily) in combination with bortezomib (weekly for 3 of 4 weeks). The MTD was defined as the highest dose level at which less than 33% of patients exhibited a dose-limiting toxicity (DLT). Efficacy, as measured by 6-month progression-free survival and response rate per RECIST, was documented. Results: Eleven patients were enrolled at three dose levels. DLTs (fatigue and rash) were seen in two of three patients at the highest dose level. Five patients were enrolled for sorafenib 400 mg b.i.d. and bortezomib 1.0 mg/m 2 weekly for 3 of every 4 weeks; none had DLTs, and this dose level was defined as the MTD. Of 10 evaluable patients, no responses were seen. Two of 11 patients (18%) remained progression free for longer than 6 months. Conclusion: The combination of sorafenib and bortezomib is safe but not active in patients with melanoma.